Status | In progress |
Process | STA |
ID number | 866 |
Provisional Schedule
Expected publication | 24 October 2018 |
Project Team
Project lead | Jeremy Powell |
Email enquiries
- If you have any queries please email TACommB@Nice.org.uk
Consultees
Companies sponsors | Steba Biotech |
Others | Department of Health |
NHS England | |
NHS Newham CCG | |
NHS City and Hackney CCG | |
Welsh Government | |
Patient carer groups | Black Health Agency |
Bob Champion Cancer Trust | |
Cancer Black Care | |
Cancer Equality | |
Everyman | |
Helen Rollason Cancer Charity | |
HAWC | |
Independent Cancer Patients Voice | |
Macmillan Cancer Support | |
Maggie’s Centres | |
Marie Curie Cancer Care | |
Muslim Council of Britain | |
Orchid | |
PCaSO | |
Prostate Cancer UK | |
Prostate Help Association | |
South Asian Health Foundation | |
Specialised Healthcare Alliance | |
Tackle Prostate Cancer | |
Tenovus Cancer Care | |
Professional groups | Association of Anaesthetists |
Association of Cancer Physicians | |
Association of Surgeons of Great Britain and Ireland | |
British Association of Urological Nurses | |
British Association of Urological Surgeons | |
British Geriatrics Society | |
British Institute of Radiology | |
British Prostate Group | |
British Psychosocial Oncology Society | |
British Society of Urogenital Radiology | |
British Uro-Oncology Group | |
Cancer Research UK | |
Pelican Cancer Foundation | |
Prostate Cancer Advisory group | |
Royal College of Anaesthetists | |
Royal College of General Practitioners | |
Royal College of Nursing | |
Royal College of Pathologists | |
Royal College of Physicians | |
Royal College of Radiologists | |
Royal College of Surgeons | |
Royal Pharmaceutical Society | |
Royal Society of Medicine | |
Society and College of Radiographers | |
UK Health Forum | |
Urology Foundation | |
UK Clinical Pharmacy Association | |
UK Oncology Nursing Society |
Commentators
Associated public health groups | Public Health England |
Public Health Wales | |
Comparator companies | None |
General commentators | All Wales Therapeutics and Toxicology Centre |
Allied Health Professionals Federation | |
Board of Community Health Councils in Wales | |
British National Formulary | |
Care Quality Commission | |
Department of Health, Social Services and Public Safety for Northern Ireland | |
Healthcare Improvement Scotland | |
Medicines and Healthcare products Regulatory Agency | |
National Association of Primary Care | |
National Pharmacy Association | |
NHS Alliance | |
NHS Commercial Medicines Unit | |
NHS Confederation | |
Scottish Medicines Consortium | |
Welsh Health Specialised Services Committee | |
Relevant research groups | Cochrane Prostatic Diseases and Urologic Cancers Group |
Institute of Cancer Research | |
MRC Clinical Trials Unit | |
National Cancer Research Institute | |
National Cancer Research Network | |
National Institute for Health Research | |
Ovarian & Prostate Cancer Research Trust | |
Pro Cancer Research Fund | |
Prostate Cancer Research Centre |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
03 January 2018 | Invitation to participate |
13 October 2016 | The technology appraisal of padeliporfin for treating localised prostate cancer (ID866) has been delayed at the request of Steba. NICE has agreed to this request because administration of the padeliporfin requires equipment that is currently not available in the NHS. NICE and Steba are exploring how this can be addressed. |
02 June 2016 | Draft scope documents |
13 May 2016 | Referral |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance